Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

PEGASUS STRENGTHENS ITS PHARMA TEAM WITH TWO STAFF APPOINTMENTS

Pegasus shortlisted for three Communiqué awards and hopes to defend its Communications Consultancy of the Year win from 2014

Infographic: PsO market snapshot

An overview of the PsO biologic and systemic patientOur PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot...

Infographic: Prostate Cancer Market Snapshot

An overview of the prostate cancer patientDownload our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by...

Infographic: LATAM

Latin AmericaThe LATAM regions largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With...

Infographic: RA market snapshot

An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...

Infographic: CEE

The Central and Eastern Europe region is home to over 145 million people and is a key global growth region. With pharmaceutical sales set to exceed $27bn in 2014, it...

Infographic: ASEAN-6

Home to over half a billion people, the ASEAN region constitutes the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an...

Infographic: HCV – The Roadblocks to Effective Treatment

Referencing data from our Living with HCV survey undertaken with patients in the US and China, this infographic explores the roadblocks encountered on the path to effective and compliant treatment.Hepatitis C is...

Turkey: Identifying the Growth Drivers

Published in eye for pharma 3 April by Marc Yates

Article: The Patient Abroad

Published in Medical Marketing & Media March 2015